| Document Date: 2014-03-10 23:11:49
Open Document File Size: 335,41 KBShare Result on Facebook
City Melbourne / / Company Melbourne Australia / Nufarm / Makhteshim Agan / Ansell Limited / Lilly / AstraZeneca / Okamoto Industries Inc / Tokyo Stock Exchange / Starpharma Holdings Limited / / Country Japan / Australia / / Currency USD / / / Event Funding / Business Partnership / / IndustryTerm dendrimer products / pharmaceutical uses / / MarketIndex ASX 300 / / MedicalCondition important cancer / bacterial vaginosis / tumour / widely used cancer / / MedicalTreatment dendrimer / dendrimers / / Organization FDA / / Person Jackie Fairley / Rebecca Wilson Mob / Nigel Baade / / / Position CEO / general public pricing pressures / Chief Executive Officer / CFO and Company Secretary / market leader / leader in the development / / Product VivaGel / Taxotere / / Technology drug delivery / / URL www.starpharma.com / /
SocialTag |
Starpharma receives $4.7M R&D tax incentive Melbourne, Australia; 11 March 2014: Starpharma (ASX: SPL, OTCQX: SPHRY) today announced it has received the anticipated $4.7M of R&D tax incentive relating to FY13 expenditure